Drug intelligence / Profile preview

AGB101 (Agni Bio)

Development stage: Preclinical
Lead developer: AgeneBio
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AGB101 is an investigational DLL3-targeted therapy being developed by Agni Bio for the treatment of small cell lung cancer (SCLC) and neuroendocrine tumors. The agent is designed to leverage Agni Bio's proprietary immune-redirection platforms, which include Vβ17-directed T memory redirection and LTβR tumor-targeted bispecifics, to engage the immune system against treatment-resistant solid tumors. AGB101 is currently in IND-enabling studies, with a Phase 1 clinical trial expected to begin in the fourth quarter of 2026.

Targets

SV2A (Synaptic vesicle glycoprotein 2A)

Beyond the preview

Go deeper on AGB101 (Agni Bio).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGB101 (Agni Bio).

Explore the full profile